Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo

PARP inhibitors (PARPi) have the potential to impact cancer therapy in a selective patient population; however, despite current patient selection methods clinical trials have shown mixed response rates. It is therefore clinically useful to determine which patients will respond prior to receiving PARPi therapy. One essential biomarker is to measure the level of PARP enzyme expression in tumors. Small molecule radiotracers have been developed to accurately quantify PARP-1 expression in vitro and in vivo.

Source: Nuclear Medicine and Biology - August 11, 2016 Category: Nuclear Medicine Authors: Redmond-Craig Anderson, Mehran Makvandi, Kuiying Xu, Brian P. Lieberman, Chenbo Zeng, Daniel A. Pryma, Robert H. Mach Source Type: research